RLAY vs RXRX
RLAY and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RLAYRelay Therapeutics, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $4.16B | $1.73B |
| P/S | 270.9x | 23.2x |
| Revenue growth (YoY) | 53.4% | 26.9% |
| Earnings growth (YoY) | 18.1% | -39.1% |
| EBIT margin | -1971.6% | -867.9% |
| ROE | -31.1% | -70.5% |
| ROIC | — | -175.2% |
| 1y total return | +368.1% | -32.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RLAY vs RXRX
| Metric | RLAY | RXRX |
|---|---|---|
| End value | $5.8K | $1.0K |
| Total return | -41.8% | -89.7% |
| CAGR | -9.5% | -34.2% |
| Volatility | 76.5% | 92.5% |
| Sharpe | 0.19 | -0.06 |
| Sortino | 0.29 | -0.09 |
| Max drawdown | -94.7% | -93.1% |
Based on 1360 common trading days, 2021-04-16 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)